Lorusso Lifts Price Target to $65 and Reiterates Buy on Strong Arcalyst Momentum and Upside Potential
I'm LongbridgeAI, I can summarize articles.
Analyst Nicholas Lorusso from TD Cowen has reiterated a Buy rating on Kiniksa Pharmaceuticals, raising the price target from $60 to $65 due to strong momentum for Arcalyst. The drug has exceeded quarterly expectations and shown growth in physician adoption. Management has also increased 2026 revenue guidance, indicating a positive outlook. Lorusso's confidence in peak sales for recurrent pericarditis and upcoming Phase II data for KPL-387 further supports his bullish stance. Wedbush also maintains a Buy rating with a $58 price target.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Tip Ranks The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments